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Abstract
Background: Myeloid cells, such as macrophages and microglia, play a crucial role in neuroinflammation and have
been recently identified as a novel therapeutic target, especially for chronic forms. The general aim would be to
change the phenotype of myeloid cells from pro- to anti-inflammatory, favoring their tissue-trophic and
regenerative functions. Myeloid cells, however, display a number of functional phenotypes, not immediately
identifiable as pro- or anti-inflammatory, and associated to ambiguous markers.
Methods: We employed in vitro assays to study macrophage polarization/differentiation in the presence of classical
polarizing stimuli such as IFNγ (pro-inflammatory) and IL4 (anti-inflammatory). We induced neuroinflammation in
mice by immunization with a myelin antigen and treated diseased mice with intracisternal delivery of an
IL4-expressing lentiviral vector. We analyzed clinical, pathological, and immunological outcomes with a focus on
myeloid cells.
Results: We found that IL6, usually considered a pro-inflammatory cytokine, was released in vitro by macrophages
treated with the anti-inflammatory cytokine IL4. We show the existence of macrophages expressing IL6 along with
classical anti-inflammatory markers such as CD206 and demonstrate that these cells are immunosuppressive in vitro.
In neuroinflamed mice, we show that IL4 delivery in the central nervous system (CNS) is associated with clinical and
pathological protection from disease, associated with increased IL6 expression in infiltrating macrophages.
Conclusions: IL6 is known to mediate both pro- and anti-inflammatory effects, having two distinct ways to induce
cell-signaling: either through the membrane bound receptor (anti-inflammatory) or through trans-signaling
(pro-inflammatory). We show here that IL6-expressing macrophages are associated to protection from
neuroinflammation, suggesting that IL6 anti-inflammatory properties prevail in the CNS, and calling for a general
reconsideration of IL6 in macrophage polarization.
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Background
Plasticity and flexibility are key features of myeloid cells,
like macrophages and microglia, and of their activation
states. To categorize macrophage functions, currently,
the M1/M2 paradigm is used [1, 2]. Generally, M1 refers
to the classically activated macrophages, whereas M2 to
the alternatively activated macrophages [3, 4]. Polarized
macrophages differ in terms of receptor expression,
cytokine production, effector functions, and chemokine
repertoires [5]. M1 macrophages are differentiated by
microbial products such as LPS, or by IFNγ produced
during an adaptive immune response by TH1 cells or
during an innate immune response by natural killer
(NK) cells. M1 macrophages have microbicidal or
tumoricidal capacity in host defense and express, among
others, iNOS, IL1β, and TNFα. Alternatively activated
macrophages differentiate in several subtypes induced by
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various stimuli: M2a induced by IL4 and IL-13, M2b in-
duced by exposure to immune complex (IC), and agonist
of toll-like receptors (TLRs) or IL-1R, and M2c induced
by IL-10 and glucocorticoids [1, 6, 7]. M2 macrophages
express IL12 at low levels but display high levels of scav-
enging, mannose, and galactose receptors, chitinase mol-
ecules such as YM1, arginase, and chemokines such as
CCL17 and CCL22. The M1/M2 paradigm is an over-
simplified model to define the functional phenotypes of
phagocytes, and in vivo macrophages can adopt a wide
array of phenotypes depending on the stimuli coming
from the tissue microenvironment [2]. Markers currently
adopted to define M1/M2 macrophages, however, are
ambiguous, and several of them can be found on both
phenotypes. One of those is IL6, classically associated to
M1 but detected also in some M2 subtypes [1, 8, 9]. IL6
is a pleiotropic cytokine, displaying both pro- and anti-
inflammatory activity [10]. IL6 pro-inflammatory activity
descriptions prevail in literature, although its ability to
promote M2 macrophage polarization has been recently
reported [11]. Macrophages, along with microglia, are
the main effector cells in experimental autoimmune en-
cephalomyelitis (EAE), the mouse model for multiple
sclerosis [12, 13]. In particular, macrophage and micro-
glia polarizations during persistent neuroinflammation
are considered a crucial event for the development of
chronic phases of multiple sclerosis, still lacking any
treatment.
We have extensively shown the therapeutic potential
of IL4 CNS gene delivery in rodent and primate models
of neuroinflammation [14–19]. In previous works, we
have associated the protective effect of IL4 to the modu-
lation of T helper lymphocytes, and especially to the in-
creased recruitment of T regulatory cells [18].
We asked the question if cells of the innate immune
system are also modulated and contribute to the thera-
peutic effect of IL4 delivery in neuroinflammation. We
show here that IL4 is able to induce IL6 release from
M2 macrophages in vitro. When delivered to the CNS
during neuroinflammation, IL4 modulates macrophage
polarization, and we found that IL6 was specifically asso-
ciated to the protective myeloid phenotype.
Methods
Bone marrow (BM)-derived macrophages in vitro culture
Bone marrow (BM) cells were flushed from femur and tibia
of C57BL/6 mice and cultured with macrophage colony-
stimulating factor, M-CSF, (100 ng ml−1, Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) in α-minimum es-
sential medium (MEM) (Invitrogen) for 7 days. The purity
of BM-macrophage cultures was confirmed by FACS using
CD11b (1:100, BD Biosciences, Mountain View, CA, USA)
and F4/80 (1:100, BioLegend, San Diego, CA, USA) anti-
bodies (average purity 80–90 %, not shown). After 7 days,
BM-derived macrophages were cultured in α-MEM
medium (Invitrogen) and differentiated to M1 and M2, re-
spectively, with rIFNγ (20 ng/ml, Peprotech, USA) and rIL4
(20 ng/ml, R&D System, Minneapolis, MN, USA) for 48 h.
Peritoneal macrophage cultures
Sterile 3 % thioglycolate (TG) was i.p. injected in
C57BL/6 mice. After 5 days, mice were sacrificed, and
peritoneal cells (Pec) were recovered by lavage with sa-
line (S.A.L.F, Bergamo, Italy). Pec were centrifuged at
1200 rpm for 10 min at 4 °C. Supernatants were elimi-
nated and pellets re-suspended in RPMI 1640 medium
supplemented with penicillin (100 U/ml), streptomicin
(100 U/ml), and ultra-glutamine (100 U/ml) (Lonza, Mi-
lano, Italy). Cells were counted with Turk’s solution
(Merck Chemicals), plated at 5 × 106 in 60-mm petri
dishes (Becton Dickinson) and then incubated at 37 °C
and 5 % CO2 for 1 h. Finally, cells were washed twice
with saline and RPMI 1640 medium supplemented with
10 % FBS, penicillin (100 U/ml), streptomicin (100 U/
ml), and ultra-glutamine (100 U/ml) was added. One
hour after incubation at 37 °C and 5 % CO2, Pec
polarization into M1 or M2 was performed by stimula-
tion with rIFNγ (20 ng/ml, Peprotech, USA) plus LPS
(100 ng/ml) for 4 h or rIL4 (20 ng/ml, R&D System,
Minneapolis, MN, USA) for 18 h.
RT-PCR analysis
RT-PCR analyses were performed on in vitro BM-derived
macrophage assay and for IL4 gene therapy studies of the
EAE model. Briefly, RNA was extracted using Trizol (Invi-
trogen) according to manufacturer’s instructions. Residual
DNA was removed by treatment with 1 U DNase per 1 μg
RNA (RQ1 RNase-free DNase, Promega) at 37 °C for
30 min. Complementary DNA (cDNA) synthesis from 3
to 5 μg total RNA was performed using Ready-To-Go
You-Prime First-Strand Beads (Amersham) and Random
Hexamer (New England Biolabs, Ipswich, MA, USA) ac-
cording to the manufacturer’s instructions. Arg-1
(Mm00475988_m1), CCL17 (Mm005161 36_m1), CD206
(Mm00485148_m1), IFNγ (Mm01168134_m1), IL-1β
(Mm01336189_m1), IL4 (Mm00445259_m1), IL6
(Mm00446190_m1), iNOS (Mm00440502_m1), TNF-α
(Mm00443258_m1), and Ym1 (Mm00657889_mH). Mes-
senger (mRNA) levels were measured by real-time RT-
PCR (Applied Biosystems, Invitrogen). The 2−ΔΔCT
method was used to calculate relative changes in gene ex-
pression [20].
Fluorescence microscopy
BM-derived and Pec macrophages, differentiated as
above, were stained for CD206 FITC (R&D) and, IL6 PE
(Becton, Dickinson) for 5 min. Cells were then fixed in
PFA 4 % for 10 min and incubated in 5 % FBS, 0.1 %
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Triton X-100, and PBS for 1 h to block any nonspecific
binding site. Nuclei were stained with DAPI. A Leica
SP5 (Leica Microsystems, Milano, Italy) confocal micro-
scope and a GE Healthcare Delta Vision were used for
image acquisitions.
Co-culture of DCs-CD4+ T cells with M2 macrophages
BM cells were differentiated in dendritic cells (DCs) for
6 days in RPMI complete medium with GM-CSF (25 ng/
ml) and rIL4 (25 ng/ml) (R&D Systems) and were acti-
vated with LPS (1 μg/ml) for 4 h. T cells were obtained
from the spleens from TCR transgenic mice (2D2) spe-
cific for the myelin oligodendrocyte glycoprotein pep-
tide, MOG 35–55 (Espikem, Florence, Italy), on the
C57Bl/6 background [21] by preparing a cell suspension
by mechanical dispersion using a cell strainer, followed
by positive selection of CD4+ cell using Miltenyi col-
umns (Miltenyi Italy). Fifty thousand activated DCs were
co-cultured with 2 × 105 CD4+ T cells and with the fol-
lowing concentration of MOG peptide: 0.3, 1, 3, 10 μM
in triplicates. These cultures were added 2 × 105 non
stimulated (NS) or M2 macrophages, as indicated, and
then incubated at 37 ° C and 5 % CO2 for 48 h.
ELISA assay for mIL4, IL-2, and IL6
mIL2 and IL6 were measured from supernatants of
DCs-CD4+ cells co-cultures with NS and M2 macro-
phages, by using a validated mouse-specific mouse IL2
and IL6 ELISA (R&D Systems). mIL4 was measured in
supernatants and lysates of infected cells or CSFs (with-
drawn from mice cisterna magna by capillarity) from
IL4-injected EAE mice, using mouse IL4 ELISA (R&D
Systems).
Generation of mouse IL4-expressing lentivirus
Murine interleukin 4 (mIL4) was obtained from a plas-
mid expressing mIL4 in an adenoviral vector (Ad-G/IL4)
[18]. The coding sequence of mIL4 was extracted with
forward and reverse primers specifically designed to con-
tain BamHI and SalI digestion sites, both synthesized by
Primm S.r.l. (Milano, Italy). A third-generation lentivirus
expressing mIL4 was generated cloning the mIL4 cDNA
in the backbone of a p277 lentiviral transfer vector and
producing a lentivirus as previously described [22]. A
GFP-expressing lentivirus was also produced to be used
as negative control in all the experiments.
Mice
Six- to 8-week-old C57Bl/6 female mice were purchased
from Charles River Laboratories (Calco, Italy). All mice
were housed in specific pathogen-free conditions, in
roomy cages, allowing free access to food and water. All
efforts were made to minimize animal suffering and to
reduce the number of mice used, in accordance with the
European Communities Council Directive of November
24, 1986 (86/609/EEC). All procedures involving animals
were performed according to the animal protocol guide-
lines prescribed by the Institutional Animal Care and
Use Committee (IACUC # 449) at San Raffaele Scientific
Institute (Milan, Italy). Because of the use of lentiviral
vectors, animals were housed in isolated cages in the
Biosafety Level 2 room of the Animal Care facility at San
Raffaele Scientific Institute.
IL4 gene therapy of EAE mouse model
Chronic EAE was induced in female C57BL/6 mice, by
subcutaneous with 300 μl of 200 μg per mouse of
MOG35–55 in Freund’s Adjuvant Incomplete liquid, IFA,
(Sigma) supplemented with 8 mg ml−1 Mycobacterium
tuberculosis (strain H37Ra; Difco, Lawrence, KS, USA).
Pertussis toxin (500 ng, List Biological Laboratories,
Campbell, CA, USA) was injected i.v. on the day of the
immunization and again 2 days later. IL4-expressing lenti-
virus or GFP-expressing lentivirus were injected in the cis-
terna magna (i.c.) of the mice at 12 d.p.i. A 30-gauge
needle attached to a Hamilton syringe was inserted into
the intrathecal space of the cisterna magna of anesthetized
mice [23]. IL4-expressing or GFP-expressing lentiviruses
(10 μl) in sterile phosphate-buffered saline (109 PFU ml−1)
were injected over 10 s. Mice were weighed and scored for
clinical signs daily up to the day of culling. Clinical assess-
ment of EAE was performed according to the following
scoring criteria: 0 = healthy, 1 = limp tail, 2 = ataxia and/or
paresis of hindlimbs, 3 = paralysis of hindlimbs and/or
paresis of forelimbs, 4 = tetraparalysis, and 5 =moribund
or death. EAE mice were killed at 34 d.p.i for real-time
PCR and histological analysis.
Preparation of CNS mononuclear cells
Mice were deeply anesthetized and perfused transcar-
dially with cold phosphate-buffered saline at the indi-
cated time point. The brains and the spinal cords were
dissected out at the desired time point, removed, and
homogenized through a 70-μm cell strainer in HBSS.
Mononuclear cells were isolated using a neural dissoci-
ation kit (Milteny Biotech) and by 30/37/70 % Percoll
(GE Healthcare) gradient centrifugation and collection
of mononuclear cells from the 37/70 % interphase.
CD11b+ cell separation
CNS mononuclear cells were spun at 300g for 10 min and
then re-suspended in cold MACS buffer (1× PBS, 0.5 %
BSA, 2 mM EDTA). Cells were incubated with biotin-
conjugated monoclonal antibodies against CD11b (Mac-1,
Rat IgG2b) (Myltenyi Biotech) at a concentration of 10 μl/
107 total cells in 40 μl MACS buffer for 10 min at 4 °C.
Anti-biotin microbeads (20 μl/107 cells in 80 μl MACS
buffer) (Myltenyi Biotech) were added to the cells and
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incubated for 15 min at 4 °C. Finally, the cells were loaded
on the MS-columns and the column-bound CD11b+ frac-
tion isolated (Myltenyi Biotech). Cells were then centri-
fuged at 300g for 10 min, and re-suspended in 500 μl of
TRizol (Invitrogen) and frozen at –80 °C.
Histological evaluation
At 34 d.p.i., at least three mice per group were perfused
through the left cardiac ventricle with saline plus EDTA
0.5 mM for 10 min followed by fixation with cold 4 %
paraformaldehyde, PFA, (Sigma) in 0.1 M phosphate
buffer (pH 7.4). Subsequently, the spinal cords and
brains from EAE mice were carefully dissected out and
post-fixed in 4 % PFA overnight and processed for cryo-
genic embedding. The quantification of neurological
damage in EAE mice was performed via histological ana-
lysis of 10-μm frozen CNS sections of control or IL4-
injected or GFP-injected EAE mice. Three different
stainings were used to detect inflammatory infiltrates
(hematoxylin and eosin), demyelination (Kluver Barrera),
and axonal damage (Bielshowsky). Neuropathological
findings were quantified on an average of 10 complete
cross sections of spinal cord per mouse taken at eight
different levels of the spinal cord. The number of peri-
vascular inflammatory infiltrates were calculated and
expressed as the numbers of inflammatory infiltrates per
square millimeter, and demyelinated areas and axonal
loss were expressed as percentage of damaged area.
Immunohistochemistry and immunofluorescence
T cells were stained using a rat anti-CD3 (pan-T cell
marker, Cat.No. MCA1477, Serotec, Oxford, UK),
CD206 positive cells were stained with rat anti-mouse
CD206 (Cat.No. MCA2235, Serotec, Oxford, UK), re-
vealed with a biotin-labeled secondary anti-rat antibody
(Cat.No. BA9400, Vector Laboratories, Burlingame, CA).
Macrophages were stained with biotin-labeled BS-I iso-
lectin B4 and IB4 (Cat.No. L2140-0, Sigma-Aldrich, St.
Louis, MO). Biotin-labeled antibodies were developed
with the ABC kit (Cat. No. PK-6200, Vector Laborator-
ies, Burlingame, CA) followed by liquid DAB+ Substrate
Chromogen System (Cat. No. K3467, Dako, Carpinteria,
CA). We also stained sections with the same rat anti-
mouse CD206 as above with a rabbit anti-mouse Iba1
(Dako, Carpinteria, CA) using fluorescent secondary
antibodies as indicated. Nuclei were stained with DAPI.
A Leica SP5 (Leica Microsystems, Milano, Italy) confocal
microscope and a GE Healthcare Delta Vision were used
for image acquisitions.
Statistical analysis
Statistical evaluations of RT-PCR data, ELISA assay, EAE
score, and immunohistochemical analyses results were
expressed as mean ± s.d. or mean ± s.e.m, as appropriate.
Results were analyzed using unpaired Student’s t test and
Mann–Whitney U test for samples with unknown and po-
tentially disparate variances. Analyses were performed
using the Prism V5.0a software (Graph-Pad, San Diego,
CA, USA). Statistical significance was ranked *P < 0.05,
**P < 0.01, and ***P < 0.001.
Results
IL6 is expressed by IL4-polarized macrophages
We obtained bone marrow macrophages from C57BL/6
mice cultivated for 7 days in the presence of M-CSF.
Cells where then polarized towards an M1 or M2
phenotype by using increasing concentrations of IFNγ
or IL4, respectively. The expression of classical M2
markers such as Ym1 and CCL17 (Fig. 1a, b) was in-
deed confined to IL4-stimulated macrophages, but also,
the pro-inflammatory cytokine IL6 was selectively
expressed in M2 cells (Fig. 1c). IL6 expression was
induced by IL4 also in peritoneal macrophages,
although at much lower levels (Additional file 1: Figure
S1). Expression of classical M1 markers such as iNOS,
IL-1β, and TNF-α (Fig. 1d–f ), were induced in IFN-γ-
stimulated macrophages in a dose-dependent way. To
verify if IL6 expression was indeed in the same cells
bearing M2 markers and not in a subpopulation of
macrophages with a different phenotype, we performed
immunofluorescence on IL4-treated macrophages. We
found co-expression of the M2 marker CD206 and IL6
in the same cells (Fig. 2).
IL6-expressing macrophages are immunosuppressive
We next asked if IL6-expressing M2 macrophages
maintained the immunosuppressive functions associ-
ated to M2 macrophages. We stimulated T cells from
2D2 mice transgenic for the TCR specific for the myelin
oligodendrocyte glycoprotein with MOG35–55, in the
presence or in the absence of IL6 expressing M2 mac-
rophages. As shown in Fig. 3, IL-2 release was signifi-
cantly inhibited in the presence of IL6-expressing M2
macrophages (Fig. 3a), while IL6 was greatly increased
(Fig. 3b). Thus, IL6-expressing M2 macrophages main-
tain their suppressive abilities.
In vivo IL4 delivery to the inflamed CNS induces the
expression of IL6 and M2 markers
To verify if IL6-expressing M2 macrophages play a role
also during in vivo inflammatory reactions, we induced
EAE in C57BL/6 mice by immunization with MOG35–55.
We injected intracisternally an IL4-expressing lentiviral
vector to induce the release of IL4 in the CSF of EAE
mice. Control mice were injected with a GFP-expressing
lentiviral vector. We found that CD11b+ myeloid cells
(macrophages and microglia) purified from EAE mice
treated with IL4 displayed reduced expression of the M1
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marker IL-1β, increased expression of the M2 marker
Ym1, and significantly increased expression of IL6, by
RT-PCR (Fig. 4a–c). Indeed, the expression of the M2
marker CD206 was significantly increased in IL4-treated
EAE mice (Fig. 5a–c).
IL6-expressing IL4-treated EAE mice are protected from
disease development
As previously described using different viral vectors
[14, 15, 18], IL4 gene therapy of EAE mice, after disease
onset, results in a significant decrease of clinical disease
Fig. 1 Gene expression of typical M1 and M2 markers in bone marrow-derived macrophages stimulated in vitro. a–f Real-time RT-PCR for Ym1,
CCL17, IL6, iNos, IL-1β, and TNF-α, in macrophages non stimulated (NS) and stimulated with different doses of IFN-γ (M1) and IL4 (M2). Gapdh has
been used as a housekeeping gene. Data are shown as fold induction (FI ± standard deviation) over NS
Fig. 2 rIL4 induces IL6 expression in CD206+ macrophages. a, b Immunofluorescent staining for CD206 (green) and IL6 (red) reveals co-localization
of IL6 and CD206 expression in bone marrow-derived (BM) macrophages, exposed to rIL4 at 20 ng/mL, but not in peritoneal (PEC) macrophages.
a ×100, scale bar = 10 μm. b ×40, scale bar = 50 μm
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severity (Fig. 6a–d). Inhibition of EAE was confirmed
also by neuropathological analysis showing a significant
decrease in demyelination and axonal loss in IL4-
treated mice (Fig. 6g–h). We confirm here that the pro-
tective effect of IL4 gene therapy in EAE is associated
to a significant increase of infiltrating CD3+ T cells,
while the number, but not the quality, of Ib4+ myeloid
cells remains unaffected (Fig. 6e, f ).
Discussion
The role of innate immunity is under scrutiny in
immune-mediated disorders because of its crucial role in
initiating inflammation, regulating immune responses,
and fostering tissue repair [2]. Investigating the role of
monocytes, infiltrating and tissue-resident macrophages
in immune-mediated disorders is complicated by the
number of different functional phenotypes they can ac-
quire [1, 2]. We replicated classical in vitro polarization
assays on bone marrow-derived and peritoneal macro-
phages. We found, surprisingly, that IL6 is associated to
M2 in bone marrow-derived macrophages and in peri-
toneal macrophages. In in vitro polarization experiments,
macrophages usually assume extreme phenotypes, probably
the only condition in which the M1/M2 paradigm holds
partially true. IL6 had been already described associated to
different M2 phenotypes, either M2b or M2c [1, 8, 9]. This
is not surprising, since several groups have reported that
macrophages in vivo usually display a blend of M1 and M2
markers, hypothesizing a spectrum of possible functional
phenotypes [8, 9]. We asked the question if in our in vitro
Fig. 3 IL4-stimulated macrophages releasing IL6 are immune-regulatory. IL4-stimulated bone marrow-derived macrophages (M2) reduce IL-2
release from MOG-TCR transgenic T lymphocytes (2D2) stimulated with MOG35–55 (a), as compared to non stimulated macrophages (NS), while
releasing high levels of IL6 (b) as measured by ELISA
Fig. 4 IL4 gene therapy induces M2 markers and IL6 expression in CNS-infiltrating CD11b+ cells in vivo. mRNA levels of IL6, IL-1β, and YM1 were
measured by real-time RT-PCR in CD11b+ cells recovered from the CNS of EAE mice treated intracisternally with an IL4-expressing (IL4) or
a GFP-expressing (GFP) lentivirus. IL4 gene therapy induces a decrease of IL-1β (a), and an increase of IL6 (b) and Ym1 (c), as compared
to control-treated mice. n = 3 for each group. Gapdh has been used as a housekeeping gene. Data are shown as arbitrary units (AU ±
standard deviation). *P < 0.05 (t test)
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assays on bone marrow-derived macrophages, we were
generating a mixture of functional phenotypes, one of them
characterized by IL6 expression, or if IL6 was indeed
expressed in cells bearing M2 markers. We found that IL6
was co-expressed, also at the protein level, by CD206+ M2
macrophages, and that these cells were immunosuppressive
in vitro, despite releasing high levels of IL6. We have not
further characterized in vitro the functional phenotype of
these macrophages, namely M2a, M2b, and M2c, because
of the ambiguity in the definition of these macrophage sub-
types, mostly defined by the polarizing stimulus. Further,
we are aware of the limitations of the in vitro suppressive
assay. We therefore resolved to move to an in vivo setting,
since we had already reported that induction of IL6 was as-
sociated to the anti-inflammatory effect of IL25 CNS gene
therapy in a mild model of neuroinflammation [24]. We
have repeatedly reported the therapeutic effect of IL4 CNS
gene therapy in mouse and primate EAE [14–19]. Since IL4
is a classical M2-polarizing stimulus for macrophages, we
asked the question if IL6 expression by infiltrating macro-
phages was associated to the protective effect of IL4 gene
transfer. We found that CD11b+ cells purified from the
brain of IL4-treated EAE mice displayed significantly in-
creased expression of IL6, along with decreased levels of
IL1β and increased levels of Ym1, thus a bona fide M2
phenotype, further confirmed by the increased levels of
CD206 we found by immunofluorescence on infiltrating
macrophages from IL4-treated EAE mice. We have cur-
rently similar findings in EAE mice successfully treated with
IL27 CNS gene therapy (manuscript in preparation).
IL6 can signal through its classical receptor, a hetero-
dimer composed by the cytokine-binding IL6R and by
gp130 transducing the signal in the cell. IL6R expression
is restricted to few cells in the CNS, while gp130 is ubi-
quitous [25]. gp130 can be activated to transduce its sig-
nal also by a complex of IL6 with the soluble form of its
receptor, generated by proteolitic shedding or alternative
splicing. This phenomenon, called trans-signaling, can
target any gp130+ cell [26]. Outside the CNS, classical
signaling is associated to IL6 protective effect, while pro-
inflammatory activities of IL6 are mediated by trans-
signaling [10]. IL6 signaling in the CNS has not been ex-
tensively studied, although trans-signaling appears to be
associated with pro-inflammatory activities also in the
brain [27–29]. Our findings suggest that in the CNS,
however, classical IL6 signaling mediating protective,
anti-inflammatory, signals may outweigh trans-signaling
and explain the increased IL6 release associated to the
protective effects of IL4 gene therapy on neuroinflam-
mation. These results are contradictory with a long list
of papers demonstrating the detrimental effects of IL6
during neuroinflammation. Among others, IL6 knock-
out (k.o.) mice are resistant to EAE [30], CNS IL6 re-
lease redirects EAE inflammation to the sites of IL6 ex-
pression [31], IL6 inhibits the conversion of Th17 to
Treg cells in the inflamed brain [32], and peripheral IL6
neutralization inhibits EAE [33]. It is not straightforward
to reconcile these observations with our data. Most of
these observations, however, rely on constitutive genetic
modifications in mice, leading to possible constitutive al-
terations of the immune system in deletion mutants on
one hand, to non physiological levels of the cytokine in
IL6 overexpressing mice, on the other. In humans,
monoclonal antibodies directed against IL6 are used in
several chronic inflammatory diseases [10], including ini-
tial trials in neuromyelitis optica [34]. Multiple sclerosis
development, however, has been reported in a patient
under anti-IL6 treatment [35], leading to suspect a
causal association [36]. Thus, targeting IL6 in the brain,
as occurs for TNFα [37], may result in worsening of
neuroinflammation, and suggests, rather, a prevailing
protective effect of IL6 in the CNS.
Fig. 5 IL4 gene therapy upregulates CD206 in CNS-infiltrating macrophages of EAE mice. Immunofluorescence spinal cord sections of C57Bl/6
mice affected by EAE and treated, at 12 d.p.i, with the GFP-expressing (GFP, a) or the IL4-expressing lentivirus (IL4, b). The staining (CD206 in
green, Iba1 in red, nuclei in blue, as indicated) highlights upregulation of CD206 in Iba1+ macrophages in EAE mice treated with IL4 gene therapy
(b) as compared to mice treated with the GFP-expressing control virus (a). a, b ×40, scale bar 10 μm. Scale quantification of CD206+ macrophages
in spinal cords is shown (± standard deviation) in (c). *P < 0.05 (t test)
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The induction of IL6 in mice protected from EAE by
IL4 gene therapy was not associated to a modulation in
the number of IB4+ cells (i.e., macrophages and micro-
glia). We confirm our previous finding that IL4 gene
therapy of EAE is associated to an increase in infiltrating
T cells that we previously described as being mostly
Foxp3+ [18, 38].
Conclusions
IL6 is mostly described as a pro-inflammatory cytokine,
associated to the development of several inflammatory
diseases. We found that IL6 is released by bone marrow-
derived macrophages polarized with IL4 towards an
anti-inflammatory, immune-regulatory, phenotype. Fur-
ther, we found that IL6 expression was increased in infil-
trating macrophages in mice protected from EAE by
CNS IL4 gene delivery. We have not direct evidence of a
protective role of IL6 per se; however, we think this data,
together with others emerging from the literature, war-
rants a reconsideration of the significance of IL6 signal-
ing during innate immune reactions in general, and
during neuroinflammation in particular.
Additional file
Additional file 1: Figure S1. Gene expression of typical M1 and M2
markers in peritoneal macrophages stimulated in vitro. (A–D) real-time
RT-PCR for iNOS, Ym1, CCI17, and iL6, in non stimulated (NS), and in
macrophages stimulated with different doses of iFn-γ (m1) and iL4 (M2).
Gapdh has been used as a housekeeping gene. Data are shown as fold
induction (Fi ± standard deviation) over NS. (TIF 42402 kb)
Abbreviations
CNS central nervous system, EAE experimental autoimmune
encephalomyelitis, MOG myelin oligodendrocyte glycoprotein, p.i post
immunization, PT pertussis toxin
Fig. 6 CNS IL4 gene therapy inhibits clinical and pathological signs of EAE. Clinical course of EAE mice intracisternally injected with the IL4-expressing
(IL4, open dots) or the GFP-expressing (GFP, closed dots) lentivirus is shown either as median (a) or mean (±standard deviation) (b) values (EAE score is
non-parametric). Arrows indicate the day of virus injection (day 12 post immunization). IL4-treated EAE mice are protected both in terms of clinical
severity (including cumulative and maximum score, a–d), and demyelination (g) and axonal loss (h). The protective effect of IL4 gene therapy is associated
to an increased number of infiltrating CD3+ T cells (e), but no modulation of IB4+ myeloid cells (f). ***P< 0.0001 (Mann–Whitney in a, t test in g); *P< 0.05
(Mann–Whitney in c, d, t test in e)
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